Clinical Trials Logo

Clinical Trial Summary

The purpose of the study was to evaluate whether LYS228 can be developed for the treatment of complicated intra-abdominal infections. It was planned that LYS228 exposure across patients with varying renal function would be evaluated during the study to confirm that LYS228 concentrations are predicted to be adequate to treat the patient population. It was planned that the PK exposure of the initial 8 patients would be analyzed. PK analysis was not conducted as per protocol the first analysis required 8 patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03354754
Study type Interventional
Source Novartis
Contact
Status Terminated
Phase Phase 2
Start date May 15, 2018
Completion date September 24, 2018

See also
  Status Clinical Trial Phase
Withdrawn NCT04240288 - Procalcitonin Guided Antibiotic Therapy N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT01473836 - A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection Phase 3
Completed NCT00965848 - A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections Phase 4
Completed NCT01506271 - Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) Phase 2
Completed NCT05628493 - Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction
Completed NCT02442596 - Abdominal SepsiS Study: Epidemiology of Etiology and Outcome N/A
Recruiting NCT04094818 - HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
Withdrawn NCT05639504 - Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)
Completed NCT00827541 - Post-Authorization Study Evaluating Safety Of Tigecycline N/A
Completed NCT01789905 - Tygacil Drug Use Investigation